The Atomo Diagnostics Ltd (ASX: AT1) share price has charged 4% higher today on the back of a positive announcement. At the time of writing, the Atomo share price is trading at 38.5 cents, up 4.05%.
The Atomo share price is on the move since the company updated the market advising it had expanded a partnership with Access Bio Inc. The agreement will see the launch of Atomo’s rapid COVID-19 antigen test in Australia, New Zealand and India.
The nasopharyngeal swab test is designed to screen for antigens produced in response to COVID-19 infections at the point of testing. This differs to the current nasal swab testing in Australia, which uses molecular PCR assays to test for coronavirus.
Atomo’s rapid test provides results after 10 minutes, as opposed to the general test kit, which is sent to a central laboratory for processing. The company said that the early identification is a breakthrough is controlling outbreaks.
In addition, Atomo noted that its rapid antigen test has the potential to work alongside its COVID-19 rapid antibody test. The latter detects whether a patient has developed antibodies to the virus, most accurately after 15 days of exposure.
Atomo will purchase the finished product from Access at a fixed price per unit. Estimated revenue earnings were not provided as Atomo seeks regulatory approvals in Australia, New Zealand and India.
The rapid antigen test is already marked for professional use in Europe and has seen significant sales thus far. In the United States, the Food and Drug Administration (FDA) is currently pending an Emergency Use Authorisation (EUA) for the new test kit.
Atomo Co-founder and Managing Director, John Kelly, was pleased with Atomo’s new expanded partnership. He said: